N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
This PHASE2/PHASE3 trial investigates Inborn Errors of Metabolism and is currently ongoing. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 4 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Completed → Active Not Recruiting
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Mendel Tuchman
For direct contact, visit the study record on ClinicalTrials.gov .